Verastem (VSTM)
NASDAQ:VSTM
Want to see VSTM full AI Analyst Report?
VSTM Stock Chart & Stats
$6.58
-$0.30(-4.59%)
At close: 4:00 PM EST
$6.58
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$4.01 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.15M
Market Cap
$527.94M
Enterprise Value$298.76M
Total Cash (Recent Filing)$204.99M
Total Debt (Recent Filing)$87.17M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.09
Shares Outstanding87,842,896
10 Day Avg. Volume1,995,927
30 Day Avg. Volume2,152,964
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue9.66
Enterprise Value/Gross Profit11.53
Enterprise Value/Ebitda-1.38
Forecast
1Y Price Target
$16.43Price Target Upside149.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$117.27M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In KRAS-mutant PatientsUpdated follow-up data indicate sustained efficacy and tolerability of the FAKZYNJA co-pack, with notably stronger benefit in KRAS‑mutant patients supporting targeted clinical use and uptake.
Commercial Launch PerformanceCommercial launch of avutometinib (FAKZYNJA) in low-grade serous ovarian cancer is outperforming expectations and provides a valuation floor that supports revenue visibility as adoption expands among academic and community physicians.
Regulatory Development PathwayStudy protocol amendments to pursue disease-specific registrational trials for the KRAS G12D inhibitor VS-7375 across multiple tumor types could streamline regulatory paths and increase the likelihood of accelerated approval opportunities.
Bears Say
Competitive LandscapeIntense competition in the KRAS inhibitor field and earlier safety concerns that required program adjustments could pressure market share and force additional changes to development plans.
Data Robustness And UncertaintySmall clinical and preclinical datasets limit confidence in the durability and generalizability of observed benefits, leaving positive signals dependent on confirmation in larger studies.
Market Adoption ConstraintsModest benefit in KRAS wild‑type patients and initial prescribing concentrated in later‑line recurrence may constrain near‑term utilization and delay broader movement of the therapy into earlier treatment lines.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $4.01 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $527.94M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is May 07, 2026 which is today.
How were Verastem’s earnings last quarter?
Currently, no data Available
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.47.
How many shares outstanding does Verastem have?
Verastem has 87,842,896 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.43 (149.67% Upside)
$16.43 (149.67% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 24.4%
Last 30 Days ▲ 24.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.63%
12-Months-Change
Fundamentals
Return on Equity
-1849.88%
Trailing 12-Months
Asset Growth
142.71%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Company Deck
VSTM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful commercial and clinical progress—an early, ahead-of-schedule FDA approval, initial revenues ($30.9M launch-period; $17.5M Q4), expanding prescriber base (~300 prescribers), strong payer access metrics, promising RAMP and VS-7375 early signals, and a pro forma cash balance (~$234.4M) with runway into H1 2027. Offsetting these positives are the NCCN guideline omission for KRAS wild-type patients, sizable year-over-year increases in absolute non-GAAP losses (+35.8% Q4; +51.9% full year), continued high R&D/SG&A spend, limited runway beyond H1 2027 without additional financing, some payer pushback on off-label use, and early-stage VS-7375 data with short follow-up. Overall the company appears to be executing a disciplined commercial launch while advancing a promising pipeline, but material risks and near-term funding/clinical timeline uncertainties persist.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$16.43
▲(149.67% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.11% Insiders
6.97% Mutual Funds
3.09% Other Institutional Investors
78.04% Public Companies and
Individual Investors